Posted on

Nih cbd oil for pain

The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities

Background: Peripheral neuropathy can significantly impact the quality of life for those who are affected, as therapies from the current treatment algorithm often fail to deliver adequate symptom relief. There has, however, been an increasing body of evidence for the use of cannabinoids in the treatment of chronic, noncancer pain. The efficacy of a topically delivered cannabidiol (CBD) oil in the management of neuropathic pain was examined in this four-week, randomized and placebocontrolled trial.

Methods: In total, 29 patients with symptomatic peripheral neuropathy were recruited and enrolled. 15 patients were randomized to the CBD group with the treatment product containing 250 mg CBD/3 fl. oz, and 14 patients were randomized to the placebo group. After four weeks, the placebo group was allowed to crossover into the treatment group. The Neuropathic Pain Scale (NPS) was administered biweekly to assess the mean change from baseline to the end of the treatment period.

Results: The study population included 62.1% males and 37.9% females with a mean age of 68 years. There was a statistically significant reduction in intense pain, sharp pain, cold and itchy sensations in the CBD group when compared to the placebo group. No adverse events were reported in this study.

Conclusion: Our findings demonstrate that the transdermal application of CBD oil can achieve significant improvement in pain and other disturbing sensations in patients with peripheral neuropathy. The treatment product was well tolerated and may provide a more effective alternative compared to other current therapies in the treatment of peripheral neuropathy.

Keywords: CBD; cannabis sativa; diabetic neuropathy; hemp; nerve pain; review..

Copyright© Bentham Science Publishers; For any queries, please email at [email protected]

Similar articles

Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S. Langford RM, et al. J Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4. Epub 2012 Nov 21. J Neurol. 2013. PMID: 23180178 Clinical Trial.

Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. Serpell M, et al. Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x. Epub 2014 Jan 13. Eur J Pain. 2014. PMID: 24420962 Clinical Trial.

Mitchell VA, Harley J, Casey SL, Vaughan AC, Winters BL, Vaughan CW. Mitchell VA, et al. Neuropharmacology. 2021 May 15;189:108529. doi: 10.1016/j.neuropharm.2021.108529. Epub 2021 Mar 16. Neuropharmacology. 2021. PMID: 33741405

Capano A, Weaver R, Burkman E. Capano A, et al. Postgrad Med. 2020 Jan;132(1):56-61. doi: 10.1080/00325481.2019.1685298. Epub 2019 Nov 12. Postgrad Med. 2020. PMID: 31711352 Clinical Trial.

Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Derry S, et al. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007393. doi: 10.1002/14651858.CD007393.pub3. Cochrane Database Syst Rev. 2013. PMID: 23450576 Updated. Review.

Cited by 22 articles

Ortiz YT, McMahon LR, Wilkerson JL. Ortiz YT, et al. Front Pharmacol. 2022 Apr 21;13:881810. doi: 10.3389/fphar.2022.881810. eCollection 2022. Front Pharmacol. 2022. PMID: 35529444 Free PMC article. Review.

Lord S, Hardy J, Good P. Lord S, et al. Curr Treat Options Oncol. 2022 Apr;23(4):514-525. doi: 10.1007/s11864-021-00934-0. Epub 2022 Mar 22. Curr Treat Options Oncol. 2022. PMID: 35316478 Free PMC article. Review.

Jazebi N, Evans C, Kadaru HS, Kompella D, Raji M, Fang F, Pappolla M, Tang SJ, Chung JM, Hammock B, Fang X. Jazebi N, et al. J Neurol Exp Neurosci. 2021;7(1):15-24. doi: 10.17756/jnen.2021-082. Epub 2021 Feb 6. J Neurol Exp Neurosci. 2021. PMID: 35252633 Free PMC article.

Failing CJ, Boehnke KF, Riebschleger M. Failing CJ, et al. Pediatr Rheumatol Online J. 2021 Dec 13;19(1):171. doi: 10.1186/s12969-021-00656-5. Pediatr Rheumatol Online J. 2021. PMID: 34903213 Free PMC article.

D’Andre S, McAllister S, Nagi J, Giridhar KV, Ruiz-Macias E, Loprinzi C. D’Andre S, et al. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211061739. doi: 10.1177/15347354211061739. Integr Cancer Ther. 2021. PMID: 34841942 Free PMC article.

Use of cannabidiol (CBD) for the treatment of chronic pain

Chronic pain can be recurrent or constant pain that lasts for longer than 3 months and can result in disability, suffering, and a physical disturbance. Related to the complex nature of chronic pain, treatments have a pharmacological and non-pharmacological approach. Due to the opioid epidemic, alternative therapies have been introduced, and components of the plant Cannabis Sativa, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have gained recent interest as a choice of treatment. The exact mechanism for CBD is currently unknown, but unlike the CBD’s psychoactive counterpart, THC, the side effects of CBD itself have been shown to be overall much more benign. The current pharmaceutical products for the treatment of chronic pain are known as nabiximols, and they contain a ratio of THC combined with CBD, which has been promising. This review focuses on the treatment efficacy of CBD, THC: CBD-based treatments for chronic pain and adverse events with each.

Keywords: cannabidiol; chronic pain; nabiximols.

Copyright © 2020. Published by Elsevier Ltd.

Conflict of interest statement

Declaration of Competing Interest The authors have no conflicts of interest to disclose.

Similar articles

Mitchell VA, Harley J, Casey SL, Vaughan AC, Winters BL, Vaughan CW. Mitchell VA, et al. Neuropharmacology. 2021 May 15;189:108529. doi: 10.1016/j.neuropharm.2021.108529. Epub 2021 Mar 16. Neuropharmacology. 2021. PMID: 33741405

Boyaji S, Merkow J, Elman RNM, Kaye AD, Yong RJ, Urman RD. Boyaji S, et al. Curr Pain Headache Rep. 2020 Jan 24;24(2):4. doi: 10.1007/s11916-020-0835-4. Curr Pain Headache Rep. 2020. PMID: 31980957 Review.

Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R. Solowij N, et al. Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35. doi: 10.1007/s00406-019-00978-2. Epub 2019 Jan 19. Eur Arch Psychiatry Clin Neurosci. 2019. PMID: 30661105 Clinical Trial.

Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT. Lichtman AH, et al. J Pain Symptom Manage. 2018 Feb;55(2):179-188.e1. doi: 10.1016/j.jpainsymman.2017.09.001. Epub 2017 Sep 18. J Pain Symptom Manage. 2018. PMID: 28923526 Clinical Trial.

Jones É, Vlachou S. Jones É, et al. Molecules. 2020 Oct 25;25(21):4930. doi: 10.3390/molecules25214930. Molecules. 2020. PMID: 33113776 Free PMC article. Review.

Cited by 7 articles

Boehnke KF, Häuser W, Fitzcharles MA. Boehnke KF, et al. Curr Rheumatol Rep. 2022 May 3:1-9. doi: 10.1007/s11926-022-01077-3. Online ahead of print. Curr Rheumatol Rep. 2022. PMID: 35503198 Free PMC article. Review.

Deckey DG, Doan M, Hassebrock JD, Patel KA, Economopoulos K, Tokish JM, Bingham JS, Chhabra A. Deckey DG, et al. Orthop J Sports Med. 2022 Apr 5;10(4):23259671221087629. doi: 10.1177/23259671221087629. eCollection 2022 Apr. Orthop J Sports Med. 2022. PMID: 35400139 Free PMC article.

Moreno-Sanz G, Madiedo A, Hernandez P, Kratz J, Aizpurua-Olaizola O, Brown MRD, López JR, Patiño J, Mendivelso FO. Moreno-Sanz G, et al. Front Pain Res (Lausanne). 2022 Mar 24;3:854795. doi: 10.3389/fpain.2022.854795. eCollection 2022. Front Pain Res (Lausanne). 2022. PMID: 35399153 Free PMC article.

Al Ubeed HMS, Bhuyan DJ, Alsherbiny MA, Basu A, Vuong QV. Al Ubeed HMS, et al. Molecules. 2022 Jan 18;27(3):604. doi: 10.3390/molecules27030604. Molecules. 2022. PMID: 35163863 Free PMC article. Review.

Filipiuc LE, Ababei DC, Alexa-Stratulat T, Pricope CV, Bild V, Stefanescu R, Stanciu GD, Tamba BI. Filipiuc LE, et al. Pharmaceutics. 2021 Nov 1;13(11):1823. doi: 10.3390/pharmaceutics13111823. Pharmaceutics. 2021. PMID: 34834237 Free PMC article. Review.